Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a long non-coding RNA transcript antisense to the ACYP2 gene. Natural antisense transcripts (NATs) are widespread in the genome and can regulate gene expression at the transcriptional or post-transcriptional level, often through interactions with their sense counterparts or by recruiting chromatin-modifying complexes[2]. While some NATs have well-established roles in gene regulation, imprinting, and disease, most remain uncharacterized, including this specific transcript. No experimental functions or roles in disease have been reported for ENSG00000296193, and there is currently no evidence that it is a therapeutically actionable target[3][2].
Not applicable; no drug-targeted mechanism is reported[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ACYP2 (ENSG00000296193).